Breaking News Instant updates and real-time market news.

ITCI

Intra-Cellular

$13.99

0.05 (0.36%)

, TSRO

TESARO

$130.76

-4.93 (-3.63%)

04:55
12/02/16
12/02
04:55
12/02/16
04:55

Leerink to hold a bus tour

10th Annual POLARxPress Bus Tour travels throughout Maryland, New York and New Jersey on November 28-December 2.

ITCI

Intra-Cellular

$13.99

0.05 (0.36%)

TSRO

TESARO

$130.76

-4.93 (-3.63%)

  • 04

    Dec

  • 07

    Dec

  • 11

    Jan

ITCI Intra-Cellular
$13.99

0.05 (0.36%)

09/29/16
PIPR
09/29/16
NO CHANGE
Target $22
PIPR
Overweight
Intra-Cellular selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Charles Duncan lowered his price target for Intra-Cellular Therapies to $22 from $57 after the company's second Phase III study in schizophrenia failed to meet the primary endpoint. The analyst, however, believes ITI-007 is "still a viable, differentiated drug candidate for treating psychosis and other symptoms." Duncan continues to see a regulatory path forward for the drug in schizophrenia, with options including another trial or submission on the current data. He views the current selloff in the shares as a buying opportunity for patient investors and reiterates an Overweight rating on Intra-Cellular.
09/29/16
COWN
09/29/16
NO CHANGE
Target $37
COWN
Outperform
Intra-Cellular price target lowered to $37 from $75 at Cowen
Cowen analyst Ritu Baral said that while it is negative for Intra-Cellular that neither the 20mg nor 60mg '007 arms reached their primary endpoint in the company's Phase 3 schizophrenia trial, the implication for '007 efficacy "is not clear cut." Encouragingly, the drugs safety was as benign as in prior studies, said Baral, who cut the firm's price target on Intra-Cellular to $37 from $75 but keeps an Outperform rating on the shares, which were downgraded to Neutral from Buy at SunTrust following the trial news.
09/29/16
RBCM
09/29/16
NO CHANGE
RBCM
Intra-Cellular should be bought on weakness, says RBC Capital
After Intra-Cellular's schizophrenia treatment, ITI-007, failed to perform statistically significantly better than placebo in a Phase 3 study, RBC Capital analyst Adnan Butt says that "early signs" suggest that "higher placebo response" was the culprit. The analyst says that ITI-0007 is safer than competing treatments, and Butt thinks that the FDA still may allow an NDA filing, which he believes would provide a catalyst for the stock in 2017. The analyst says that the stock's risk/reward ratio is positive at current levels. He cut his price target on the shares to $49 from $74 but keeps an Outperform rating on the stock.
11/01/16
RBCM
11/01/16
NO CHANGE
RBCM
Intra-Cellular risk/reward 'compelling,.' says RBC Capital
RBC Capital analyst Adnan Butt says the Street "has largely written off" Intra-Cellular's ITI-007 drug, but the analyst thinks that the FDA could still allow the company to file an NDA if data on the drug comes back positive. The analyst says that the drug, which treats schizophrenia, is differentiated from its competitors from a safety perspective. He believes that the drug "is approvable," and he says that the stock's risk/reward is "compelling." He keeps a $49 price target and an Outperform rating on the shares.
TSRO TESARO
$130.76

-4.93 (-3.63%)

11/04/16
SBSH
11/04/16
NO CHANGE
Target $151
SBSH
Buy
Citi boosts TESARO target to $151 on niraparib upside opportunities
Citi analyst Robyn Karnauskas raised her price target for TESARO to $151 from $125 following the drugmaker's Q3 results. The stock closed yesterday down $3.07 to $120.28. The niraparib filing is on track while the Varubi launch is better than expectations, Karnauskas tells investors in a research note. She believes TESARO's immuno-oncology franchise is not getting credit and sees longer-term upside opportunities for niraparib. Karnauskas keeps a Buy rating on the shares.
11/04/16
11/04/16
DOWNGRADE

Market Perform
TESARO downgraded to Market Perform on valuation at Raymond James
As previously reported, Raymond James downgraded TESARO to Market Perform from Outperform. Analyst Christopher Raymond said his thesis is largely play out and shares have hit his previously price target of $120.
11/07/16
RBCM
11/07/16
NO CHANGE
RBCM
Several biotech names de-risked, should be bought, says RBC Capital
RBC Capital analyst Adnan Butt names Aerie Pharmaceuticals (AERI), The Medicines Co. (MDCO), Seattle Genetics (SGEN), and TESARO (TSRO) as biotech companies that face little risk and whose stock should be bought at current levels.The Phase 3 data on Aerie's Rhopressa indicates that the drug should be approved for glaucoma, while The Medicines Co's "Carbavance for gram negative infections looks good and PCSK9si for LDL-C lowering is differentiated," the analyst thinks. The commercial opportunity of Seattle Genetics' Adcetris could increase, while the company has multiple anti-cancer drugs beginning Phase 3 trials, and TESARO's Niraparib appears likely to be approved, and its label could be expanded, Butt believes.
11/09/16
COWN
11/09/16
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics price target lowered to $40 from $47 at Cowen
Cowen analyst Boris Peaker lowered his price target on Heron Therapeutics (HRTX) to $40 from $47 following the company's Q3 results. The analyst expects a slow sales ramp for Sustol due to competition, reimbursement dynamics, and Tesaro's (TSRO) early experience with its launch of Varubi. Peaker maintained his Outperform rating on Heron Therapeutics shares.

TODAY'S FREE FLY STORIES

LNC

Lincoln National

$70.82

-0.87 (-1.21%)

06:13
02/27/17
02/27
06:13
02/27/17
06:13
Conference/Events
Lincoln National management to meet with Evercore ISI »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

DB

Deutsche Bank

$19.13

-0.58 (-2.94%)

06:12
02/27/17
02/27
06:12
02/27/17
06:12
Periodicals
Deutsche Bank bonus cuts not leading to 'mass exodus,' Reuters reports »

Cuts in Deutsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

AES

AES Corp.

$11.93

0.18 (1.53%)

06:11
02/27/17
02/27
06:11
02/27/17
06:11
Earnings
Breaking Earnings news story on AES Corp. »

AES Corp. sees FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

LBTYA

Liberty Global

$36.99

0.56 (1.54%)

06:11
02/27/17
02/27
06:11
02/27/17
06:11
Conference/Events
Liberty Global management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

AES

AES Corp.

$11.93

0.18 (1.53%)

06:10
02/27/17
02/27
06:10
02/27/17
06:10
Earnings
AES Corp. sees 8%-10% annual growth in EPS, cash flow through 2020 »

Expects 8% to 10% average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

AES

AES Corp.

$11.93

0.18 (1.53%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Earnings
AES Corp. reports Q4 adjusted EPS 35c, consensus 36c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

SHOO

Steven Madden

$37.15

-0.1 (-0.27%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Upgrade
Steven Madden rating change  »

Steven Madden upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SYT

Syngenta

$85.27

0.3 (0.35%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Periodicals
ChemChina's Syngenta bid seen receiving conditional EU approval, Reuters says »

The EU is set to give…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRX

BioCryst

$5.49

-0.11 (-1.96%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Hot Stocks
BioCryst reports 'positive' interim results from APeX-1 trial »

BioCryst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

06:07
02/27/17
02/27
06:07
02/27/17
06:07
Hot Stocks
Buffett says market 'not in bubble territory' or 'anything of the sort' »

Warren Buffett, while…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

, KR

Kroger

$33.29

0.3 (0.91%)

06:06
02/27/17
02/27
06:06
02/27/17
06:06
Periodicals
Wal-Mart launching price-comparison test in U.S., targeting Aldi, Reuters says »

Wal-Mart (WMT) is…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

KR

Kroger

$33.29

0.3 (0.91%)

PG

Procter & Gamble

$91.05

-0.08 (-0.09%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

CAG

Conagra Brands

$41.16

0.66 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

LJPC

La Jolla

$19.87

1.65 (9.06%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Hot Stocks
La Jolla announces positive results from ATHOS-3 Phase 3 study of LJPC-501 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$45.61

1.36 (3.07%)

06:04
02/27/17
02/27
06:04
02/27/17
06:04
Downgrade
PSEG rating change  »

PSEG downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Hot Stocks
Breaking Hot Stocks news story on UCP, Inc. »

UCP, Inc. reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LAUR

Laureate Education

$13.24

0.06 (0.46%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:02
02/27/17
02/27
06:02
02/27/17
06:02
Earnings
UCP, Inc. reports Q4 EPS 89c with benefits, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNAP

Snap Inc.

06:01
02/27/17
02/27
06:01
02/27/17
06:01
Periodicals
Snap founders tightened grip following dispute with Lightspeed, NYT reports »

Early Snap investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

GRAM

Grana y Montero

$3.32

-1.77 (-34.77%)

06:00
02/27/17
02/27
06:00
02/27/17
06:00
Downgrade
Grana y Montero rating change  »

Grana y Montero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

05:59
02/27/17
02/27
05:59
02/27/17
05:59
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.66

0.13 (0.10%)

, EBAY

eBay

$34.06

0.46 (1.37%)

05:58
02/27/17
02/27
05:58
02/27/17
05:58
Periodicals
Tech firms plan to file brief in favor of transgender rights, Axios reports »

Leading tech companies…

AAPL

Apple

$136.66

0.13 (0.10%)

EBAY

eBay

$34.06

0.46 (1.37%)

IBM

IBM

$181.35

-0.3 (-0.17%)

MSFT

Microsoft

PYPL

PayPal

$43.07

0.54 (1.27%)

CRM

Salesforce

$81.78

-0.29 (-0.35%)

YELP

Yelp

$33.46

-0.01 (-0.03%)

BOX

Box

$17.93

0.41 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 09

    May

AFL

Aflac

$71.71

-0.01 (-0.01%)

05:57
02/27/17
02/27
05:57
02/27/17
05:57
Upgrade
Aflac rating change  »

Aflac upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

FTI

TechnipFMC

$32.30

-0.58 (-1.76%)

05:56
02/27/17
02/27
05:56
02/27/17
05:56
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$57.00

2.32 (4.24%)

, ISIL

Intersil

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$57.00

2.32 (4.24%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.